|
1) Kirkwood TB, Austad SN. Why do we age？ Nature. 2000; 408: 233-8
|
|
|
|
2) Vijg J, Campisi J. Puzzles, promises and a cure for ageing. Nature. 2008; 454: 1065-71
|
|
|
|
|
|
3) Rose M, Charlesworth B. A test of evolutionary theories of senescence. Nature. 1980; 287: 141-2
|
|
|
|
|
|
4) Stearns SC, Ackermann M, Doebeli M, et al. Experimental evolution of aging, growth, and reproduction in fruitflies. Proc Natl Acad Sci U S A. 2000; 97: 3309-13
|
|
|
|
|
|
5) Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000; 408: 239-47
|
|
|
|
|
|
6) Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005; 120: 449-60
|
|
|
|
|
|
7) Piper MD, Bartke A. Diet and aging. Cell Metab. 2008; 8: 99-104
|
|
|
|
|
|
8) Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009; 325: 201-4
|
|
|
|
|
|
9) Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006; 354: 1685-97
|
|
|
|
|
|
10) Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991; 121: 1244-63
|
|
|
|
|
|
11) Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007; 369: 1208-19
|
|
|
|
|
|
12) Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation. 2004; 110: 1507-12
|
|
|
|
|
|
13) Remuzzi G, Perico N, Macia M, et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005; Suppl: S57-65
|
|
|
|
|
|
14) Iwai M, Liu HW, Chen R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004; 110: 843-8
|
|
|
|
|
|
15) Wang J, Ho L, Chen L, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007; 117: 3393-402
|
|
|
|
|
|
16) Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008; 22: 2465-75
|
|
|
|
|
|
17) Rhodes DR, Ateeq B, Cao Q, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009; 106: 10284-9
|
|
|
|
|
|
18) Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003; 112: 67-75
|
|
|
|
|
|
19) Linz W, Jessen T, Becker RH, et al. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation. 1997; 96: 3164-72
|
|
|
|
|
|
20) Linz W, Heitsch H, Scholkens BA, et al. Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension. 2000; 35: 908-13
|
|
|
|
|
|
21) Ferder L, Inserra F, Romano L, et al. Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. Am J Physiol. 1993; 265: C15-8
|
|
|
|
|
|
22) Basso N, Cini R, Pietrelli A, et al. Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol. 2007; 293: H1351-8
|
|
|
|
|
|
23) Ferder L, Romano LA, Ercole LB, et al. Biomolecular changes in the aging myocardium: the effect of enalapril. Am J Hypertens. 1998; 11: 1297-304
|
|
|
|
|
|
24) Ferder LF, Inserra F, Basso N. Advances in our understanding of aging: role of the renin-angiotensin system. Curr Opin Pharmacol. 2002; 2: 189-94
|
|
|
|
|
|
25) Benigni A, Corna D, Zoja C, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009; 119: 524-30
|
|
|
|
|
|
26) Haigis MC, Guarente LP. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006; 20: 2913-21
|
|
|
|
|
|
27) Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD＋-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 2007; 21: 920-8
|
|
|
|
|
|
28) Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD＋ levels dictate cell survival. Cell. 2007; 130: 1095-107
|
|
|
|
|
|
29) Thompson MM, Oyama TT, Kelly FJ, et al. Activity and responsiveness of the renin-angiotensin system in the aging rat. Am J Physiol Regul Integr Comp Physiol. 2000; 279: R1787-94
|
|
|
|
|
|
30) Kunieda T, Minamino T, Nishi J, et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation. 2006; 114: 953-60
|
|
|
|
|
|
31) Herbert KE, Mistry Y, Hastings R, et al. Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ Res. 2008; 102: 201-8
|
|
|
|
|
|
32) Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8: 729-40
|
|
|
|
|
|
33) Oliverio MI, Kim HS, Ito M, et al. Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc Natl Acad Sci U S A. 1998; 95: 15496-501
|
|
|
|
|
|
34) Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354: 2443-51
|
|
|
|
|